Yahoo Finance • 20 hours ago
Protagonist Therapeutics shares soared more than 30% Friday after The Wall Street Journal reported that the biopharma company was in talks with Johnson & Johnson about a possible acquistion. See more ... Continue Reading Visualizza comme... Full story
Yahoo Finance • 21 hours ago
Yahoo Finance Anchor Josh Lipton reports on three stories Wall Street is watching in the latest Market Minute: US stocks tumble as US-China trade tensions intensify, Protagonist Therapeutic (PTGX) shares surge on WSJ reports of acquisition... Full story
Yahoo Finance • 21 hours ago
Health care stocks were lower Friday afternoon, with the NYSE Health Care Index and the Health Care PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 22 hours ago
Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 23 hours ago
Check out the companies making the biggest moves midday: Rare earth stocks — The group rose broadly after President Donald Trump said China was holding the world "captive" over the minerals, threatening countermeasures. MP Materials traded... Full story
Yahoo Finance • 24 hours ago
Investing.com -- Protagonist Therapeutics (NASDAQ:PTGX) stock spiked 10% before being halted for volatility after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the biotech company. The potential... Full story
Yahoo Finance • 24 hours ago
Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ [https://s... Full story
Yahoo Finance • 3 days ago
Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics ( PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • last month
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • 2 months ago
Protagonist Therapeutics (NASDAQ:PTGX) President and CEO Dinesh V. Patel, Ph.D., sold 10,415 shares of common stock on July 25, 2025, at prices ranging from $54.75 to $54.82, for a total value of $570,533. The sale comes as the $3.48 billi... Full story
Yahoo Finance • 2 months ago
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • 3 months ago
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head... Full story
Yahoo Finance • 3 months ago
Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism. Continue Reading View Comments... Full story
Yahoo Finance • 4 months ago
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story
Yahoo Finance • 4 months ago
Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company focused on developing novel therapies, has been making significant strides in its drug development pipeline. The company’s recent advancements in its lead candidates... Full story
Yahoo Finance • 4 months ago
For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening their blood and increasing the risk for cl... Full story
Yahoo Finance • 5 months ago
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop... Full story
Yahoo Finance • 8 months ago
We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now.In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against the other cheap biotech stocks. Biotech Stocks F... Full story
Yahoo Finance • last year
Turnstone Biologics Corp. SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure... Full story
Yahoo Finance • 2 years ago
Overview of Steven Cohen (Trades, Portfolio)'s Recent Stock Transaction Warning! GuruFocus has detected 5 Warning Signs with PTGX. Steven Cohen (Trades, Portfolio)'s firm, Point72 Asset Management, has recently made a notable adjustment... Full story